Quantcast

Latest Human Genome Sciences Stories

2009-08-03 10:10:00

ROCKVILLE, Md., Aug. 3 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the closing of its public offering of 26,697,250 newly issued shares of its common stock at a price to the public of $14.00 per share, which includes 3,482,250 shares sold upon exercise by the underwriters of their option to purchase additional shares. The net proceeds to the Company from the offering are approximately $356.7 million, after deducting the underwriting discount and...

2009-07-28 18:45:00

ROCKVILLE, Md., July 28 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the pricing of its underwritten public offering of 23,215,000 newly issued shares of its common stock at a price to the public of $14.00 per share. The size of the offering was increased from the originally announced 18,000,000 shares. The Company also granted the underwriters a 30-day option to purchase up to an additional 3,482,250 shares of the Company's common stock. The...

2009-07-27 15:11:00

ROCKVILLE, Md., July 27 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has commenced an underwritten public offering of up to 18,000,000 shares of its common stock. The Company intends to grant the underwriters a 30-day option to purchase up to an additional 2,700,000 shares of the Company's common stock. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and...

2009-07-23 09:24:21

After a 50-year drought in Lupus treatments, scientists announce positive results from a clinical trial for a new drug. After a year-long trial, patients treated with BENLYSTA had improvement in overall disease activity without significant flare-ups compared to patient who receved the placebo.  The patients receiving the drug also were able to reduce their intake of steroid medications.  The study is the largest ever to be completed for lupus and the first Phase III trial of a new...

2009-07-22 15:05:00

ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced financial results for the quarter ended June 30, 2009, and provided highlights of recent key developments. (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) "Both BENLYSTA(TM) and ZALBIN(TM) (formerly Albuferon(R)) continued to make excellent progress toward commercialization in the second quarter of 2009," said H. Thomas Watkins, President and Chief Executive...

2009-07-22 06:00:00

ROCKVILLE, Md., July 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Government has exercised its option to purchase an additional 45,000 doses of raxibacumab (ABthrax(TM)) for the Strategic National Stockpile, to be delivered over a three-year period, beginning near the end of 2009. HGS expects to receive approximately $151 million from this award as deliveries are completed. (Logo:...

2009-07-20 13:15:13

The experimental drug Benlysta shows great promise in treating lupus and could be available to the public late next year, its Maryland-based developer said. Benlysta is the first promising new treatment for lupus, an autoimmune disease, in nearly 50 years, researchers at Human Genome Sciences, of Rockville, said. Pending the results of another round of tests, the company plans to file for U.S. Food and Drug Administration approval early next year, said David C. Stump, the firm's head of drug...

0193b7f3ed783a72d334f02a791a058f1
2009-07-20 15:17:47

Human Genome Sciences Inc. reported on Monday that a late-stage clinical trial of its experimental lupus drug Benlysta had shown success in reducing symptoms of the disease. The news, which was reported just after midnight, shocked many who had dismissed the product, and caused shares of the company's stock to soar 274 percent. Results of the 52-week, 867-person trial showed that patients taking a high dose of Benlysta, which is administered once a month by IV infusion, had a 57.6 percent...

2009-07-19 23:40:00

First Phase 3 Lupus Drug Trial in Decades to Show Effectiveness NEW YORK, July 20 /PRNewswire-USNewswire/ -- The Lupus Research Institute (LRI) and its National Coalition of state and local organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline on the highly promising results of this landmark clinical trial of Benlysta(TM) (belimumab) for people with systemic lupus. "We are very hopeful that we now are strongly on our way to the first new treatment for lupus in 50...

2009-07-19 23:33:00

BENLYSTA(TM) SUCCESSFUL IN FIRST OF TWO PIVOTAL CLINICAL TRIALS WASHINGTON, July 20 /PRNewswire-USNewswire/ -- Today, Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from a year-long clinical trial of BENLYSTA for treating lupus. When the 52-week study concluded, the lupus patients who were treated with BENLYSTA had improvement in overall disease activity without clinically significant flare-ups in one or more isolated organs when compared to patients who...


Word of the Day
cruet
  • A vial or small glass bottle, especially one for holding vinegar, oil, etc.; a caster for liquids.
This word is Middle English in origin, and ultimately comes from the Old French, diminutive of 'crue,' flask.
Related